Elutia Inc.
14
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
21.4%
3 terminated/withdrawn out of 14 trials
76.9%
-9.6% vs industry average
0%
0 trials in Phase 3/4
70%
7 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
EluPro Antibiotic-Eluting BioEnvelope Registry
Role: lead
CIED Implantation in Low BMI Patients
Role: lead
CanGaroo® Registry Study
Role: lead
ViBone in Cervical and Lumbar Spine Fusion
Role: lead
A Retrospective Breast Reconstruction Study
Role: lead
Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation
Role: lead
Evaluation Of New Onset Postoperative Atrial Fibrillation
Role: lead
A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope
Role: lead
Retrospective Experience Of CIED Implantation
Role: lead
CorMatrix ECM for Carotid Repair Following Endarterectomy Registry
Role: lead
Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)
Role: lead
A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction
Role: lead
A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Role: lead
A Study Evaluating 3-Level OLIF Spine Fusion
Role: lead
All 14 trials loaded